NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Gary,

There is nothing tricky in putting EDEN system into operation. We can clearly see that from Advent. You need certain grade clean room, freezer facility, well train operators. Merck has all these in place. Not only Merck, here is some descriptions from AmplifyBio. NWBO can certainly put its EDEN in AmplifyBio clean rooms by renting.

Phase 1 of the 350,000-square-foot manufacturing facility will open in the first quarter of 2024. It will include standalone B- and C-grade suites that can be configured to accommodate any modality and simultaneously produce multiple lots. The manufacturing suites are complemented by quality, process development, and expansive analytics laboratories staffed by experts at AmplifyBio to ensure that clients have access to a development “sandbox” of assay platforms, technologies, and expertise anchored in experienced GMP quality assurance and facility management.

If you check carefully, you can see that Merck has no vaccines in any form pending for approval. For Merck to start massive constructions of vaccine manufacturing facilities with crazy working hours and hire all high-caliber talents in the area of immunology, cell therapy, and cell manufacturing, Merck must have seen something definitive. There is nothing more definitive than DCVax-L. Period! The deal with Daiichi which has the FDA approved oral CSF1R inhibitor, the only one on this planet also gives us the indication that Merck is aiming at including plx3397 in the further combination trial which has been going on for several years at UCLA.